Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $15.14.

Several equities analysts have recently issued reports on CATX shares. UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price for the company. Royal Bank of Canada decreased their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research report on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Oppenheimer lowered their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd.

Perspective Therapeutics Trading Up 5.8 %

NYSE CATX opened at $4.36 on Friday. The company has a fifty day moving average price of $10.60 and a 200-day moving average price of $12.27. Perspective Therapeutics has a 1 year low of $2.28 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Equities research analysts forecast that Perspective Therapeutics will post -0.87 EPS for the current year.

Insider Buying and Selling

In related news, CEO Johan M. Spoor purchased 14,500 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at approximately $574,832.16. This represents a 10.54 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the acquisition, the chief financial officer now owns 48,800 shares of the company’s stock, valued at approximately $186,416. This represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 33,595 shares of company stock valued at $126,625. Company insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after purchasing an additional 4,566,356 shares during the period. FMR LLC raised its position in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares in the last quarter. State Street Corp boosted its stake in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Finally, Nicholson Wealth Management Group LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $21,390,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.